Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Tiffany M. Yu, Pravin U. Dugel, Julia A. Haller, Peter K. Kaiser, Renée J.G. Arnold

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea ® ). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan. Materials & methods: VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted. Results: With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month. Conclusion: Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.

Original languageEnglish
Pages (from-to)1195-1207
Number of pages13
JournalJournal of Comparative Effectiveness Research
Volume7
Issue number12
DOIs
StatePublished - 1 Dec 2018

Keywords

  • pharmacolysis
  • vitreoretinal adhesion
  • vitreoretinal traction

Fingerprint

Dive into the research topics of 'Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA'. Together they form a unique fingerprint.

Cite this